JP2020528911A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528911A5 JP2020528911A5 JP2020504146A JP2020504146A JP2020528911A5 JP 2020528911 A5 JP2020528911 A5 JP 2020528911A5 JP 2020504146 A JP2020504146 A JP 2020504146A JP 2020504146 A JP2020504146 A JP 2020504146A JP 2020528911 A5 JP2020528911 A5 JP 2020528911A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antigenic
- reprna
- ivt
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 95
- 230000000890 antigenic effect Effects 0.000 claims description 50
- 102000004169 proteins and genes Human genes 0.000 claims description 39
- 108090000623 proteins and genes Proteins 0.000 claims description 39
- 230000037452 priming Effects 0.000 claims description 19
- 230000002163 immunogen Effects 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 230000028993 immune response Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 241000701161 unidentified adenovirus Species 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- 241000598171 Human adenovirus sp. Species 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 230000036039 immunity Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538070P | 2017-07-28 | 2017-07-28 | |
| US62/538,070 | 2017-07-28 | ||
| US201762546259P | 2017-08-16 | 2017-08-16 | |
| US62/546,259 | 2017-08-16 | ||
| PCT/US2018/044075 WO2019023566A1 (en) | 2017-07-28 | 2018-07-27 | METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528911A JP2020528911A (ja) | 2020-10-01 |
| JP2020528911A5 true JP2020528911A5 (enExample) | 2021-08-26 |
| JP7311489B2 JP7311489B2 (ja) | 2023-07-19 |
Family
ID=63407511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020504146A Active JP7311489B2 (ja) | 2017-07-28 | 2018-07-27 | 異種ｒｅｐＲＮＡ免疫化のための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11235051B2 (enExample) |
| EP (1) | EP3658179B1 (enExample) |
| JP (1) | JP7311489B2 (enExample) |
| KR (1) | KR102806640B1 (enExample) |
| CN (1) | CN111163799A (enExample) |
| AU (1) | AU2018306614B2 (enExample) |
| BR (1) | BR112020001052A2 (enExample) |
| CA (1) | CA3071011A1 (enExample) |
| IL (1) | IL272281B2 (enExample) |
| MA (1) | MA49693A (enExample) |
| SG (1) | SG11202000019RA (enExample) |
| WO (1) | WO2019023566A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020121273A1 (en) * | 2018-12-14 | 2020-06-18 | Glaxosmithkline Biologicals Sa | Heterologous prime boost vaccine compositions and methods |
| US11026894B2 (en) | 2019-01-10 | 2021-06-08 | Massachusetts Institute Of Technology | Lipid nanoparticles and use thereof to deliver RNA polynucleotides |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| EP4061405A1 (en) | 2019-11-18 | 2022-09-28 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| AU2021233816A1 (en) | 2020-03-09 | 2022-10-06 | Arcturus Therapeutics, Inc. | Coronavirus vaccine compositions and methods |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| BR112023002642A2 (pt) | 2020-08-14 | 2023-04-04 | Arcturus Therapeutics Inc | Método para liofilizar nanopartículas lipídicas |
| CN116867517A (zh) | 2021-02-23 | 2023-10-10 | 扬森疫苗与预防公司 | 三聚体稳定性hiv包膜蛋白突变 |
| AR125191A1 (es) | 2021-03-22 | 2023-06-21 | Lifeedit Therapeutics Inc | Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso |
| CN115232824B (zh) * | 2021-04-22 | 2023-09-26 | 中国人民解放军军事科学院军事医学研究院 | 一种基于1083骨架的预防狂犬病毒感染的疫苗 |
| US20240400619A1 (en) * | 2021-09-02 | 2024-12-05 | Replicate Bioscience, Inc. | Modified alphaviruses with heterologous nonstructural proteins |
| WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
| CN116064597B (zh) * | 2023-01-17 | 2024-04-26 | 北京大学 | 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| ES2335657T3 (es) | 2002-04-25 | 2010-03-31 | Crucell Holland B.V. | Medios y metodos para la produccion de vectores de adenovirus. |
| WO2004001032A2 (en) | 2002-04-25 | 2003-12-31 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
| EP1687033A4 (en) | 2003-11-12 | 2008-06-11 | Us Navy | IMPROVEMENT OF VACCINE-INDUCED IMMUNE REACTIONS AND PROTECTION THROUGH HETEROLOGY REINFORCEMENT WITH ALPHAVIRUS REPLICON VACCINE |
| ES2871907T3 (es) | 2004-01-23 | 2021-11-02 | Msd Italia Srl | Portadores de vacuna de adenovirus de chimpancé |
| WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
| WO2008136845A2 (en) | 2007-04-30 | 2008-11-13 | Medtronic Minimed, Inc. | Reservoir filling, bubble management, and infusion medium delivery systems and methods with same |
| WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| MX2011007980A (es) | 2009-02-02 | 2011-08-17 | Okairos Ag | Secuencias de acido nucleico y aminoacido de adenovirus de simio, vectores que contienen los mismos y usos de las mismas. |
| US20110300205A1 (en) | 2009-07-06 | 2011-12-08 | Novartis Ag | Self replicating rna molecules and uses thereof |
| SI3178490T1 (sl) | 2009-07-15 | 2022-08-31 | Glaxosmithkline Biologicals S.A. | Sestavki proteina F RSV-ja in postopki za pripravo le-teh |
| PL2590676T3 (pl) | 2010-07-06 | 2017-02-28 | Glaxosmithkline Biologicals Sa | Wirionopodobne cząstki dostarczające dla autoreplikujących się cząsteczek rna |
| CN103370411B (zh) | 2010-12-14 | 2016-05-04 | 美国卫生和人类服务部 | 腺病毒血清型26和血清型35线状病毒疫苗 |
| WO2012141984A1 (en) * | 2011-04-08 | 2012-10-18 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| EP2729168A2 (en) * | 2011-07-06 | 2014-05-14 | Novartis AG | Immunogenic compositions and uses thereof |
| MX378747B (es) | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| US20140271714A1 (en) * | 2013-03-15 | 2014-09-18 | Monika Simmons | Induction of an immune response against dengue virus using the prime-boost approach |
| JP2017527564A (ja) * | 2014-09-03 | 2017-09-21 | バヴァリアン ノルディック エー／エス | 免疫応答の増進を目的とする方法及び組成物 |
| WO2016187613A1 (en) * | 2015-05-21 | 2016-11-24 | Janssen Vaccines & Prevention B.V | Methods and compositions for inducing protective immunity against filovirus infection and/or disease |
-
2018
- 2018-07-27 BR BR112020001052-9A patent/BR112020001052A2/pt unknown
- 2018-07-27 AU AU2018306614A patent/AU2018306614B2/en active Active
- 2018-07-27 US US16/634,205 patent/US11235051B2/en active Active
- 2018-07-27 SG SG11202000019RA patent/SG11202000019RA/en unknown
- 2018-07-27 JP JP2020504146A patent/JP7311489B2/ja active Active
- 2018-07-27 CA CA3071011A patent/CA3071011A1/en active Pending
- 2018-07-27 KR KR1020207005743A patent/KR102806640B1/ko active Active
- 2018-07-27 MA MA049693A patent/MA49693A/fr unknown
- 2018-07-27 EP EP18762177.6A patent/EP3658179B1/en active Active
- 2018-07-27 CN CN201880063070.8A patent/CN111163799A/zh active Pending
- 2018-07-27 WO PCT/US2018/044075 patent/WO2019023566A1/en not_active Ceased
- 2018-07-27 IL IL272281A patent/IL272281B2/en unknown
-
2021
- 2021-12-22 US US17/645,556 patent/US11964007B2/en active Active